A citation-based method for searching scientific literature

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters, Sangeeta Sawhney, Paul Strumph. Diabetes Care 2018
Times Cited: 76



Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta, Darren K McGuire, Anne L Peters, John Reed, Sangeeta Sawhney, Paul Strumph. Diabetes Care 2018
Times Cited: 88




List of shared articles



Times cited

Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research.
Amber L Beitelshees, Bruce R Leslie, Simeon I Taylor. Diabetes 2019
11

Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.
Helena W Rodbard, Andrea Giaccari, Rosemarie Lajara, John Stewart, Paul S Strumph, Juliana Oliveira, Pablo Lapuerta, Rita Castro. Diabetes Obes Metab 2020
2

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora. Diabetes Ther 2020
7

Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol.
Satish K Garg, Anne L Peters, John B Buse, Thomas Danne. Diabetes Technol Ther 2018
37

New Medications for the Treatment of Diabetes.
Satish K Garg, Dominique Giordano. Diabetes Technol Ther 2019
0

NICE guidance on sotagliflozin for type 1 diabetes.
Amanda I Adler, Jessica Cronshaw, Carl Prescott, Sanjeev Patel, Eleanor Donegan, Jasdeep Hayre. Lancet Diabetes Endocrinol 2020
3

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. BMJ 2019
39

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Thomas Danne, Jeremy Pettus, Andrea Giaccari, Bertrand Cariou, Helena Rodbard, Stuart A Weinzimer, Mireille Bonnemaire, Sangeeta Sawhney, John Stewart, Stella Wang,[...]. Diabetes Technol Ther 2019
6

Sotagliflozin: First Global Approval.
Anthony Markham, Susan J Keam. Drugs 2019
12

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Anne L Peters, Darren K McGuire, Thomas Danne, Jake A Kushner, Helena W Rodbard, Ketan Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J Davies,[...]. Diabetes Care 2020
1

Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Kexin Li, Gaosi Xu. J Diabetes 2019
10

Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2.
Thomas Danne, Steven Edelman, Juan Pablo Frias, Francisco Javier Ampudia-Blasco, Philip Banks, Wenjun Jiang, Michael J Davies, Sangeeta Sawhney. Diabetes Obes Metab 2021
0

Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes.
Daniël H van Raalte, Petter Bjornstad. Nephrol Dial Transplant 2020
4

Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Christian Hampp, Richard S Swain, Casie Horgan, Elizabeth Dee, Yandong Qiang, Sarah K Dutcher, Andrew Petrone, Rong Chen Tilney, Judith C Maro, Catherine A Panozzo. Diabetes Care 2020
14

Evaluation of the safety of sodium-glucose co-transporter-2 inhibitors for treating patients with type 1 diabetes.
Weihao Wang, Lina Zhang, Xiaobei Pei, Qi Pan, Lixin Guo. Diabetes Obes Metab 2020
2

Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor.
Rhea Teng, Martin Kurian, Kelly L Close, John B Buse, Anne L Peters, Charles M Alexander. Diabetes Spectr 2021
0

Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
Bryony E Langford, Marc Evans, Tao Haskins-Coulter, Molly O'Connor, Harriet E O Cant, Lucy A Eddowes, Christopher Edmonds, Amarjeet Tank. Diabetes Obes Metab 2020
5

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
Bruce A Perkins, Julio Rosenstock, Jay S Skyler, Lori M Laffel, David Z Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T George,[...]. Diabetes Care 2019
3

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
Daniël H van Raalte, Petter Bjornstad, Frederik Persson, David R Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J L Heerspink, David Cherney. Diabetes Care 2019
10

A review of sotagliflozin for use in type 1 diabetes.
Wesley Nuffer, Briana Williams, Jennifer M Trujillo. Ther Adv Endocrinol Metab 2019
3

Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.
Lunwen Rao, Chenhong Ren, Shan Luo, Chenghu Huang, Xuefeng Li. Acta Diabetol 2021
0

Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Kajal Patel, Antonia Carbone. Ann Pharmacother 2019
7

Pharmacological therapies to address obesity in type 1 diabetes.
Anna Casu, Anika Bilal, Richard E Pratley. Curr Opin Endocrinol Diabetes Obes 2020
0

Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Schafer Boeder, Steven V Edelman. Diabetes Obes Metab 2019
15

Empagliflozin in type 1 diabetes.
Chantal Mathieu, Laura Van Den Mooter, Bert Eeckhout. Diabetes Metab Syndr Obes 2019
2

Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.
Helena W Rodbard, Andrea Giaccari, Bertrand Cariou, Satish Garg, Michael J Davies, Kiernan Seth, Sangeeta Sawhney. Diab Vasc Dis Res 2021
0

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
25

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
27

Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
9

Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care.
Emma G Wilmot, Pratik Choudhary, Lalantha Leelarathna, Mike Baxter. Diabetes Obes Metab 2019
9

Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes.
Marc S Rendell. Expert Rev Endocrinol Metab 2018
3

SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Matthew C Riddle, William T Cefalu. Diabetes Care 2018
10

Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
Torben Biester, Olga Kordonouri, Thomas Danne. Diabetes Obes Metab 2019
5

Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures.
Jeremy H Pettus, Jake A Kushner, Virginia Valentine, Richard Wood, Christianne Pang, Sachin Paranjape, Rachele Berria, Antonio Deluzio, Steven E Edelman. Diabetes Technol Ther 2019
3

What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
13

Defining and characterising diabetic ketoacidosis in adults.
Ketan K Dhatariya. Diabetes Res Clin Pract 2019
4

Sotagliflozin: A Review in Type 1 Diabetes.
Emma D Deeks. Drugs 2019
3

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin.
Marc S Rendell. Drug Des Devel Ther 2019
2

Non-insulin therapies in addition to insulin in Type 1 DM treatment.
Andrea Llano, Gerard A McKay. Br Med Bull 2020
1

Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes.
Diana Isaacs, Stephanie Yager, Marcie Parker, Lauren Wolfe, Jennifer Luxenburg, Sanela Lekic. Ann Pharmacother 2019
3

Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update.
Sanjay Kalra, Kimi K Shetty, Vertivel B Nagarajan, Jignesh K Ved. Diabetes Ther 2020
4

Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.
Ning Li, Ruimin Chen, Kewei Liu. Clin Drug Investig 2020
1

Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Giovanni Musso, Antonio Sircana, Francesca Saba, Maurizio Cassader, Roberto Gambino. PLoS Med 2020
0

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.
Tamara Y Milder, Sophie L Stocker, Dorit Samocha-Bonet, Richard O Day, Jerry R Greenfield. Eur J Clin Pharmacol 2019
3

Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.
Bruce W Bode, Eda Cengiz, R Paul Wadwa, Phillip Banks, Thomas Danne, Jake A Kushner, Darren K McGuire, Anne L Peters, Paul Strumph, Sangeeta Sawhney. Diabetes Technol Ther 2021
0

SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects.
Birgit Janssens, Simon Caerels, Chantal Mathieu. Ther Adv Endocrinol Metab 2020
3

Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Jennifer R Snaith, Deborah J Holmes-Walker, Jerry R Greenfield. Trends Endocrinol Metab 2020
5

Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Jingli Lu, Lijuan Tang, Haiyang Meng, Junjie Zhao, Yan Liang. Diabetes Metab Res Rev 2019
10

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F Scheerer, Nayyar Iqbal, Paresh Dandona. Diabetes Obes Metab 2020
12

Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.
Thomas Danne, Vijay N Joish, Marion Afonso, Phillip Banks, Sangeeta Sawhney, Pablo Lapuerta, Michael J Davies, John B Buse, Dee Lin, Matthew Reaney,[...]. Diabetes Technol Ther 2021
1


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy